To determine if the chronic administration of enalapril, an inhibitor of angiotensin
converting enzyme (ACE), reduces progression of cardiac dysfunction in pediatric oncology
patients who have received anthracyclines, and who are not currently on digoxin, diuretics,
or vasodilators for heart failure.